ARCHER trial shows benefit of ANX007 on vision loss in geographic atrophy
By: Michela Cimberle Fact checked by Christine Klimanskis, ELS BARCELONA, Spain — In the phase 2 ARCHER trial, ANX007, a novel C1q inhibitor with neuroprotective properties, showed consistent protection against loss of…